| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-01-10 | Selvita (Poland) Chiesi Farmaceutici (Italy) | chemistry research | respiratory, cardiovascular and special care disorders | R&D |
Cardiovascular diseases - Respiratory diseases | R&D agreement |
| 2014-01-10 | Santaris Pharma (Denmark) GSK (UK) | Locked Nucleic Acid (LNA) technology | licensing |
Licensing agreement | ||
| 2014-01-10 | Nuevolution (Denmark) Novartis (Switzerland) | Chemetics® technology | licensing |
Technology - Services | Licensing agreement | |
| 2014-01-10 | InteRNA Technologies (The Netherlands) UCB (Belgium) University of Bonn (Germany) | miRNAs | neurodegenerative diseases | R&D |
Neurodegenerative diseases | R&D agreement |
| 2014-01-10 | BioNTech (Germany) Ganymed Pharmaceuticals (Germany) | R&D facility | opening of new premises |
Cancer - Oncology | Opening of new premises | |
| 2014-01-09 | Isarna Therapeutics (Germany) Sanofi (France) | commercial-grade antisense oligonucleotide (ASO) compounds | manufacturing |
Cancer - Oncology | Production agreement | |
| 2014-01-09 | Santaris Pharma (Denmark) Roche (Switzerland) | RNA targeted medicines using Santaris Pharma\'s proprietary Locked Nucleic Acid (LNA) Drug Platform. | undisclosed | R&D |
undisclosed | R&D agreement |
| 2014-01-09 | ILiAD Biotechnologies (USA) Inserm (France) Inserm Transfert (France) Institut Pasteur de Lille (France) | live attenuated Bordetella pertussis vaccine technology, including BPZE1 | Bordetella pertussis infection | collaboration |
Infectious diseases | Licensing agreement |
| 2014-01-09 | Lonza (Switzerland) Index Ventures (Switzerland) | process development and cGMP production | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-01-09 | Epigenomics (Germany - USA) Wuhan Kindstar Clinical Diagnostics (China) | Epi proLung® | lung cancer | licensing |
Diagnostic - Cancer - Oncology | Licensing agreement |
| 2014-01-09 | Avillion (UK) Pfizer (USA - NY) | Bosulif® (bosutinib) | chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) | clinical research development |
Cancer - Oncology - Rare diseases | Clinical research agreement |
| 2014-01-09 | BiogenIdec (USA - CA) Sangamo BioSciences (USA - MA) | ZFN genome-editing technology | hemoglobinopathies including sickle cell disease (SCD) and beta-thalassemia | licensing collaboration |
Genetic diseases- Hematological diseases | Licensing agreement |
| 2014-01-08 | AstraZeneca (UK) Immunocore (UK) | novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-01-08 | Santaris Pharma (Denmark) Isarna Therapeutics (Germany) | Locked Nucleic Acid (LNA) technology | TGF-Beta-mediated diseases | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-01-08 | BioLineRx (Israel) JHL Biotech (Taïwan) | BL-9020 | type 1 diabetes | development |
Metabolic diseases | Development agreement |
| 2014-01-08 | Bayer (Germany) Peking University (China) | R&D |
Cardiovascular diseases - Cancer - Oncology - Hematological diseases - | R&D agreement | ||
| 2014-01-08 | XTL Biopharmaceuticals (Israel) Yeda Research and Development Company (Israel) | hCDR1 | systemic lupus erythematosus | licensing |
Autoimmune diseases | Licensing agreement |
| 2014-01-07 | Horizon Discovery (UK) AstraZeneca (UK) | drug targets | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-01-07 | Epirus Switzerland (Switzerland) Ranbaxy (India) | BOW015 (biosimilar version of Remicade® (infliximab)) | licensing | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement | |
| 2014-01-07 | Boehringer Ingelheim (Germany) Crystal Bioscience (USA) | therapeutic antibodies | R&D |
Technology - Services | R&D agreement |
